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METHODS FOR PERSONALIZED MEDICINE: FACTOR MIXTURE MODELS 
FOR INVESTIGATING DIFFERENTIAL RESPONSE TO TREATMENT
Stull D1, Wyrwich KW2, Frueh FW3
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Bethesda, MD, 
USA, 3Medco Health Solutions, Inc., Bethesda, MD, USA
If all patients responded to treatment in a similar way, there would be little or no 
variability in outcomes within treatment groups. Experience suggests otherwise,
raising the question, what accounts for this variability in response? Some of the het-
erogeneity in response may be attributable to observed variables that are included as 
covariates in analyses (age, gender, dose, dosing schedule or missed doses, comorbidi-
ties); some may be the result of unobserved but potentially identiﬁ able factors, such 
as genetics. Still others may involve data that are collected as part of the trial but are
not explicitly included as covariates in analyses such as baseline levels of variables or 
changes in study variables. In this latter case, the cause of heterogeneity must be 
inferred from the data. Methods have been developed to aid in categorization of 
responders but these methods are not used to full advantage in trials and outcomes
studies. Factor mixture models are a combination of common factor and latent class 
analysis that can be used to explore unobserved population heterogeneity. Mixture 
models can be used to identify trial patients that exhibit within-class homogeneity yet
are themselves different categorically from other classes of patients; this method
enables identiﬁ cation of variables that may account for the categorical differentiation.
This session demonstrates the use of mixture models for uncovering such subgroups 
as hyper- or hypo-responders to treatment in the context of clinical trials. Examples 
from a clinical trial and a simulation study are presented to show how these subgroups
and their characteristics are detected. Other methods for exploring what personal
characteristics of trial enrolees inﬂ uence treatment response using logistic and polyto-
mous regression will also be demonstrated.
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COMPARISON OF ANALYTIC APPROACHES TO ESTIMATE 
INCREMENTAL EXPENDITURES: A CASE OF OTITIS MEDIA AMONG
CHILDREN IN THE UNITED STATES
Kamble S1, Bharmal M2
1University of North Carolina at Charlotte, Charlotte, NC, USA, 2Quintiles, Inc, Falls Church, 
VA, USA
OBJECTIVES: To compare different approaches to estimate incremental expenditures
using an example of estimating the direct cost of treating Otitis Media (OM) among
children in the US. METHODS: Three approaches; covariate matched case-control
(CM), probability matched case-control (PM), and the generalized linear regression 
(i.e., GLM with log-link and gamma variance function) with standard risk adjustment, 
were developed using the 2005 Medical Expenditure Panel Survey (MEPS) data. 
Children with OM (age 18 years; n  9,691) were identiﬁ ed using International 
Classiﬁ cation of Diseases (ICD)-9 diagnosis codes 381 or 382 for OM. All three ap-
proaches included age, sex, race, ethnicity, education, region, insurance, and number
of medications used (proxy for comorbidity) as covariates. For the CM method, OM
cases were matched with non-OM controls exactly on categorical variables and on the 
largest possible absolute difference (AD) of 0 (vs. 5) for the two continuous variables 
(age and education). For the PM method, the case-control match was obtained using
predicted probability of OM with an AD of 0.01 (vs. 0.0001). The estimated incre-
mental expenditures and the number of matched pairs obtained using the above 
approaches were compared. RESULTS: The number of matched pairs ranged from 907
children for CM with AD  0 to 1,664 children for PM with AD  0.01. In contrast, 
the GLM approach included the entire sample (n  9,691) for the analysis. Incremental
expenditures associated with OM using the CM method were lowest (median difference 
[MD] range: $197.68 to $213.98) followed by GLM approach (mean difference: 
$245.6) and highest using the PM method (MD: $275.89 and $299.79). The mean 
differences using the CM and PM methods varied widely. CONCLUSIONS: Based on
the relative ease in computing, use of the entire sample for analysis, and the consider-
ation for the distribution function of expenditure data, GLM with standard risk 
adjustment may be a preferred approach to estimate incremental expenditures.
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FINITE MIXTURE REGRESSIONS IN MODELING PRESCRIPTION DRUG
UTILIZATION AND PRESCRIPTION DRUG EXPENDITURES OF PATIENTS 
WITH REUMATOID ARTHRITIS (RA)
Kim J
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: Finite mixture regression models have been used to estimate skewed 
distributions. However, mixture models have not been broadly considered in outcomes 
research. This study examined whether mixture regressions gave a better ﬁ t to the 
data than regressions with single distribution when estimating prescription drug utili-
zation and prescription drug expenditures with high positive skewness. METHODS:
The Medical Expenditure Panel Survey which is a nationally representative survey 
with comprehensive information on health care use and spending was used to estimate 
prescription drug utilization and prescription drug expenditures of adult patients (q20 
years old) with RA in 2005. Poisson distributions to estimate prescription drug utiliza-
tion and gamma distributions to estimate prescription drug expenditures were consid-
ered. Bayesian information criteria (BIC) were used to compare regression models. 
RESULTS: A total of 4,546 patients with a diagnosis of RA (mean age: 60.3 years, 
female: 65.0%) were included in the study. Mean number of prescriptions was 31
(median: 21). Skewness and Kurtosis in number of prescriptions were 1.9 and 8.2,
respectively. Mean expenditure on prescription drugs was $2050.80 (median:
$1210.50). Skewness and Kurtosis in expenditure on prescription drug were 8.4 and 
170.4, respectively. After controlling demographic and clinical variables, a mixture
model with two Poisson distributions (BIC: 28,735) gave a better ﬁ t to the drug utiliza-
tion data than a model with a Poisson distribution (BIC: 114,339) and a negative 
binomial model (BIC: 38,559). A mixture model with two gamma distributions (BIC: 
35,806) gave a better ﬁ t to the drug expenditure data than a model with a gamma
distribution (BIC: 36,208). CONCLUSIONS: This study showed that mixture models
provided better ﬁ ts to the data with high positive skewness than regression models 
with single distribution when estimating the number of prescriptions and the prescrip-
tion drug expenditures of patients with RA.
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INSTRUMENTAL VARIABLE APPROACH IN OUTCOMES RESEARCH
Baser O1, Dysinger A2
1University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2STATinMED
Research, Ann Arbor, MI, USA
OBJECTIVES: To review the efﬁ cacy of instrumental variable models in addressing a
variety of assumption violations to ensure standard ordinary least squares estimates
are consistent. Instrumental variable models gained popularity in outcomes research 
because of their ability to consistently estimate the average causal effects even in the 
presence of unmeasured confounding. However, in order for this consistent estimation
to be achieved several conditions must hold. In this paper, we provide an overview of 
the instrumental variable approach, examine possible tests to check the prerequisite
conditions, and illustrate how weak instruments may produce inconsistent and inefﬁ -
cient results. METHODS: We use two instrumental variables and apply Shea’s partial
R-square method, the Anderson canonical correlation, and Cragg-Donald tests to 
check for weak instruments. Hall-Pexie tests are applied to see if any of these instru-
ments are redundant in the analysis. RESULTS: A total of 15,956 asthma patients
from a private payer data set were examined in this study. We used controller-reliever
copay ratio and physician/practice prescribing patterns as an instrument. We demon-
strated that the former was a weak and redundant instrument producing inconsistent
and inefﬁ cient estimates of the effect of treatment. The results were worse than the 
results from standard regression analysis. CONCLUSIONS: Despite the obvious 
beneﬁ t of instrumental variable models, the method should not be used blindly. Several
strong conditions are required for these models to work, and each of them should be 
tested. Otherwise, the results will be statistically worse than the results achieved by
simply using standard ordinary least squares.
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DEVELOPMENT OF AN INTERACTIVE MODEL TO EVALUATE THE
ECONOMIC IMPACT OF CHD EVENTS AMONG ADULTS WITH
DYSLIPIDEMIA FROM AN EMPLOYER PERSPECTIVE
Menzin J1, Lang K1, Zhang B1, Korn JR1, Simko RJ2, Zachry WM3, Patel NV2
1Boston Health Economics, Inc, Waltham, MA, USA, 2Abbott Laboratories, Abbott Park, IL, 
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OBJECTIVES: Coronary heart disease (CHD) is associated with one-half of all car-
diovascular events in the US among working-age adults, with an estimated cost of 
$156.4 billion in 2008. Several lifestyle and treatment interventions are associated 
with reductions in CHD events and mortality. Our goal was to develop an interactive 
model based on rigorous analytic methods that would enable employers to assess, 
through the use of a simple interface, the expected occurrence of CHD events and
associated costs among covered employees and retirees with dyslipidemia. METHODS:
An analytic model framework was developed to estimate expected CHD events and 
costs from an employer perspective. Model inputs include demographics, presence of 
CHD risk factors, employment details (active vs. retired; full-time vs. part-time; 
salary), direct medical costs of CHD events, work-loss (disability insurance details,
worker replacement scenarios), and discount and medical cost inﬂ ation rates. Default
input parameter values are based on nationally-representative NHANES data, com-
mercial insurance claims data, and published literature. The model interface allows 
employers to modify default values to ﬁ t their population and to conduct sensitivity 
analyses. Prediction equations derived from NHANES data and Framingham risk 
equations are used along with employer data to predict the expected number of CHD 
events and the proportion achieving lipid goals. Employer costs are calculated based 
on the predicted number of events, medical costs per event, and indirect costs resulting 
from absenteeism. RESULTS: Model outputs include the percentage of employees/
retirees expected to reach lipid control targets, expected number of CHD events, and
total costs associated with CHD events (sum of direct and indirect costs). Employer-
speciﬁ c results are compared to national benchmarks. CONCLUSIONS: This interac-
tive model illustrates how pragmatic outcomes research can be converted into a 
transparent tool addressing serious health care budget issues that is readily understood
by a diverse set of corporate managers.
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EXTENDING RANDOM EFFECT MODELS TO CENSORED COST DATA
Baser O1, Yuce H2, Gust C3
1University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2STATinMED
Research and The City University of New York, Brooklyn, NY, USA, 3STATinMED Research, 
Ann Arbor, MI, USA
OBJECTIVES: Challenges in analyzing cost data include addressing skewness in cost
distributions, observed and unobserved heterogeneity across samples, and even more
challenging complexities due to censoring. We combined generalized random effect
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models with inverse probability weighted (IPW) estimation techniques to address those 
challenges in a single model. METHODS: Generalized random effect models were used 
with weights that are calculated as inverse of probability being uncensored. The Gauss-
ian family and log link function were chosen. We applied a test to see if possible censor-
ing bias exists. We also calculated the deviation from the consistent value if standard 
pooled ordinary least squares were used. RESULTS: A total of 4,824 observations were 
used in the analysis. We obtained Medicare claim ﬁ les for the two years following a 
lung-cancer diagnosis. Costs had high kurtosis and skewness. Moreover, 30% of the
cases were censored. Therefore, their annual costs were not observed. The total cost 
of all care is $60K for the two years following a lung-cancer diagnosis and $55K for
incomplete cases. Results signiﬁ cantly diverged from the standard regression model 
(p  0.000). CONCLUSIONS: This paper applies the inverse probability weighted 
estimation to an inception cohort of patients newly diagnosed with lung cancer. Our
ﬁ ndings suggest that the standard regression model yields an inconsistent estimator due
to censoring bias. IPW least square estimation method removes that bias.
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A REVIEW OF THE EVOLUTION OF HEALTH ECONOMIC MODELS OF
SMOKING CESSATION
Fisher MI1, Muston D2, Knight CJ1
1Heron Evidence Development Ltd, Luton, UK, 2Heron Evidence Development Ltd, Stopsley, 
Luton, UK
OBJECTIVES: To review how health economic models of the cost-effectiveness of 
smoking cessation interventions have evolved over the last ten years. METHODS: The 
Medline database was searched via PubMed using the keywords ‘cost-effectiveness
models smoking cessation’. Articles not available or dating before 1998 were excluded.
The abstracts from these results were examined, and relevant studies were selected for 
the review. A bibliographic search was implemented on the selected studies and addi-
tional relevant studies were included. An extraction grid was built to record key 
comparable attributes of each included model as reported. RESULTS: Thirteen studies 
were included and extracted, dating from 1999–2008. The most common model 
design was Markov model simulations of hypothetical patient cohorts given various
interventions (6 studies). Reported cost perspectives have widened over the period: 
since 2004, societal perspectives have been the most common (7/8 studies) whereas
previously direct perspectives were more common (4/5 studies). Prior to 2004, 
3/5 studies were of UK patients whereas since then 4 were for the US, 3 Scandinavia.
The interventions included in the models were initially Nicotine Replacement 
Therapy (NRT) and bupropion (Zyban), but this has widened recently to also include 
varenicline (Champix), which was approved by the FDA in May 2006. It was not
possible to draw clear conclusions as to the values of cost, health outcome and cost-
effectiveness made given the wide variety of study designs, perspectives and countries 
modelled and the small number of studies. CONCLUSIONS: There is wide variety in
the nature of published health economic models of smoking cessation in terms of 
perspective, country and model structure. Some trends have been observed. Markov
models were the most common model design to use for modelling smoking cessation 
cost-effectiveness in the articles we reviewed.
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USE OF STABILIZED INVERSE PROPENSITY SCORES AS WEIGHTS TO
DIRECTLY ESTIMATE RELATIVE RISK AND ITS CONFIDENCE INTERVALS
Xu S1, Ross C1, Raebel MA1, Shetterly S1, Blanchette CM2, Smith DH3
1Kaiser Permanente Colorado, Denver, CO, USA, 2Lovelace Respiratory Research Institute, 
Albuquerque, NM, USA, 3Center for Health Research, Kaiser Permanente Northwest, 
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OBJECTIVES: Inverse propensity scores have been used in observational studies to 
reduce selection bias. To obtain estimates of the main effects, a pseudo data set is
created with weights copies of observations for each subject and analyzed with con-
ventional regression models. Currently variance estimation requires speciﬁ c formulas 
depending on type of outcomes. Our goal is to demonstrate a statistical approach to 
directly obtain the correct estimates of variance of the main effects (usually group
difference in outcomes) in regression models. METHODS: We carried out theoretical 
and simulation studies to show that the variance of the main effects estimated directly 
from regressions is underestimated, and that the type I error rate is higher due to the
inﬂ ated sample size in the pseudo data. We propose to use the stabilized weights to 
directly estimate both the main effect and its variance from conventional regression 
models. RESULTS: We applied the approach to a study examining the effectiveness
of serum potassium monitoring in reducing hyperkalemia-associated adverse events
among 27,362 diabetic patients newly-prescribed a renin-angiotensin-aldosterone
system (RAAS) inhibitor from three HMO Research Network sites. The relative risk
(with monitoring versus without monitoring) and conﬁ dence intervals were 0.52 (0.39, 
0.70) using stabilized weights compared to 0.52 (0.43, 0.64) using typical inverse
propensity scores. The sample size in the pseudo data using the stabilized weights was 
27,312 compared to 54,632 using inverse propensity scores. The sample size in the
pseudo data using the stabilized weights is slightly smaller than the original 27,362
largely due to missing covariates in the propensity score model. CONCLUSIONS: Our 
theoretical, simulation results, and real data example demonstrate that the use of the
stabilized weights in the pseudo data preserves the sample size of original data, pro-
duces correct estimation of the variance of main effect, and maintains an appropriate
type I error rate.
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“UNNATURAL” HISTORY: MODELING DISEASE PROGRESSION USING
OBSERVATIONAL DATA
Noyes K1, Bajorska A1, Chappel AR2, Schwid S1, Mehta LR2, Holloway R1, Dick A3
1University of Rochester School of Medicine, Rochester, NY, USA, 2University of Rochester, 
Rochester, NY, USA, 3The RAND Corporation, Pittsburgh, PA, USA
OBJECTIVES: Cost-effectiveness analysis requires comparison of outcomes in treated 
and untreated populations. Data from randomized clinical trials (RCT) do not provide 
progression rates representative of the general population, while treatment effects in
observational data may be biased due to non-randomization. We developed a novel 
approach for estimating untreated progression rates (controls) by using data from a 
nationally representative patient cohort, as well as RCT estimates. METHODS: We 
used data from the 2000–2005 Sonya Slifka multiple sclerosis (MS) cohort. Disease 
progression was characterized by disability-based disease states and relapses. We 
modeled probabilities of disease state transitions using a ﬁ rst-order annual Markov
model that adjusted for age, gender, disease duration, recent relapse rates, prior states,
and the speciﬁ c disease-modifying therapy (DMT). We developed an iterative multi-
nomial logistic regression algorithm, constraining the effects of DMT to match those 
reported by RCTs. RESULTS: After correcting for the DMT treatment effects and 
other observable risk factors, the probability of disability progression was greater for 
estimates based on all MS patients compared to the estimates based on untreated
individuals only. The 95% conﬁ dence intervals using the entire cohort (including 
treated and untreated individuals) were narrower than the intervals based on the 
subsample of untreated patients. CONCLUSIONS: Our results indicate that 
the untreated patients in our study had lower estimates of disease progression than
the treated patients would have had if they remained untreated. This suggests that
patients who forgo treatment are likely to have milder, slower progressing forms of 
MS. Correcting for treatment effects in a more inclusive group of patients likely pro-
vides a more realistic estimate of disease progression than simply characterizing pro-
gression in an untreated cohort. The use of a broader cohort also improves the
precision of disease progression estimates.
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A FACTORIAL SIMULATION OF THE GAINS FROM AN EMPIRICAL BAYES
APPROACH OVER CLASSICAL METHODS
Murray JF1, Fryback DG2
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of Wisconsin-Madison, Madison, WI, 
USA
OBJECTIVES: Classical methods assume that any and all information exists only in 
the data; Empirical Bayes (EB) methods assume, under certain conditions, that an 
informative prior can be calculated from the data. We conducted a simulation to show
the gains achieved by EB over classical methods. METHODS: We assumed that 
exchangeable units of analysis are available from which to calculate prior information. 
A non-parametric prior was estimated as a mixture of normal distributions. The simu-
lation used a two-level, four factor design to generate one-hundred and sixty scenarios.
The factors varied were: (1) the number of units of analysis [25, 50], (2) the sample 
size within each unit of analysis [10 or 25], (3) the number of distributions within the
mixture [2 or 4] and (4) the average effect sizes between the distributions within the 
prior mixture [0.2 and 0.8 standard deviations]. A prior was estimated for each sce-
nario using the EM algorithm across all units of analysis. This prior was combined
with the individual data to estimate posterior means; bootstrap methods were used to
estimate Bayesian conﬁ dence intervals. The Bayesian and Classical results were com-
pared within scenarios on four measures of “goodness”: (1) Absolute difference 
between the “true” mean and the classical and EB estimates, (2) frequency of the EB
mean being closest to the “true” mean, (3) average widths of the EB and classical
intervals, and the actual probability coverage of the estimated intervals. RESULTS:
EB methods were consistently closer in absolute difference and were more frequently 
closer to the “true” mean. EB conﬁ dence intervals were consistently narrower giving 
less uncertainty about the location of the true mean while maintaining the expected
probability coverage. CONCLUSIONS: Using “prior” information based on certain 
assumptions, Empirical Bayes methods provide better estimates of means and conﬁ -
dence intervals compared to classical methods.
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REGRESSION ESTIMATORS FOR QUALITY OF LIFE AND QUALITY-
ADJUSTED LIFE YEARS (QALYS)
Basu A1, Manca A2
1University of Chicago, Chicago, IL, USA, 2University of York, York, UK
OBJECTIVES: Unlike the literature on estimators for cost data, not much attention
has been paid to the appropriate use of regression estimators for the analysis of health
beneﬁ ts in economic evaluation, i.e. EQ5D and QALYs. We explored the use of Beta 
regression models to address characteristics – such as ceiling effect, truncated distribu-
tion, and heteroschedasticity – typical of any quality of life data. METHODS: We 
developed both a single equation and a two-part Beta regression models (Classical and 
Bayesian), deﬁ ned incremental and marginal effects of covariates on the mean EQ5D, 
and proposed relevant estimators. Using the UK multicentre EVALUATE trial as a
motivating example, we compared results from OLS regression to those obtained from
our Beta-based estimators in terms of estimated mean treatment effect after controlling 
for other covariates. We complemented the case study with a microsimulation exercise. 
RESULTS: The OLS regression ﬁ t the EVALUATE trial EQ5D data as well as any of 
the advanced estimators based on Beta distribution. The estimated treatment effects
were 0.0099 (SE  0.011; 90% CI: 0.022, 0.038) under standard OLS regression 
